Long-Acting Cabotegravir Well Tolerated in Pregnant Women
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 8, 2024 -- Long-acting injectable cabotegravir (CAB-LA) appears to be well tolerated in pregnant women, according to a study presented at AIDS 2024, the 25th International AIDS Conference, held from July 22 to 26 in Munich.
Sinead Delany-Moretlwe, M.B.B.Ch., Ph.D., from the University of the Witwatersrand in South Africa, and colleagues reported on maternal safety and pregnancy outcomes among 2,472 participants in the HPTN 084 open-label extension. Pregnancies were categorized by exposure to CAB-LA injections during pregnancy, CAB-LA injections before pregnancy only, and no CAB-LA exposure (tenofovir disoproxil fumarate/emtricitabine [TDF/FTC] group).
The researchers identified 351 confirmed incident pregnancies in 334 participants during 3,118 person-years (incidence, 11.3/100 person-years). The median time from last injection to pregnancy detection was eight and 13 weeks among participants with CAB-LA use during or prior to pregnancy, respectively. Participants with CAB-LA use during pregnancy received a median of four injections. No maternal deaths were reported. The incidence of pregnancy-related maternal adverse events was 43.7, 52.9, and 40.0 per 100 person-years among those using CAB-LA during pregnancy, those using prior to pregnancy, or those without CAB-LA exposure, respectively. Across groups, poor pregnancy outcome rates were similar, with negative outcomes reported in 28, 35, and 26 percent of pregnancies with CAB-LA use during pregnancy, prior to pregnancy, or without CAB-LA exposure, respectively. There was one major congenital anomaly (in the group receiving CAB-LA during pregnancy).
"We hope that these findings can fill an important knowledge gap that can help increase access to this highly effective HIV preexposure prophylaxis option among cisgender women before, during, and after pregnancy," Delany-Moretlwe said in statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Considerable Decline Seen in Self-Reported Maternal Mental Health
THURSDAY, May 29, 2025 -- From 2016 to 2023, there was a considerable decline in self-reported maternal mental health, while declines in physical health were smaller, according to...
Unconditional Cash Transfer May Increase Breastfeeding Rates
THURSDAY, May 29, 2025 -- Unconditional cash transfers (UCTs) through U.S. social programs may increase breastfeeding rates, including in persons with low income, according to a...
ACP Issues Clinical Guideline for Statin Use in Persons With HIV
THURSDAY, May 29, 2025 -- In a clinical guideline issued by the American College of Physicians and published online May 27 in the Annals of Internal Medicine, recommendations are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.